the World over, work intensely on a possible vaccine against covid-19, which has affected more than 20 million people worldwide.
the Way to get approved for a medicinal product is, however, a long and usually takes several years since there are high requirements for the documentation that must be presented.
More than 160 different attempts to develop a vaccine in time, and a good handful of these have reached the so-called phase 3.
It is both chinese and western attempts that has reached the last phase before the product is approved for use.
Here you can get an overview of the western companies that perform the phase 3 trials of a vaccine against covid-19:
American company, which at the end of July started a phase 3 study with around 30,000 participants. The potential vaccine has the name mRNA-1273 and covers, to working with mRNA, messenger RNA, which is a part of the body's cells. With technology one can get the body's own cells to produce antibodies against, for example, covid-19. The company has received 955 million - dollar 6.4 billion dollars - from the u.s. government to vaccinekandidaten.
The two companies from Germany and the UNITED states cooperate on a vaccine, which also work with mRNA. Here was a combined phase 2 and 3 study started in the end of July, with 30,000 participants in the UNITED states and countries such as Argentina and Germany. The UNITED states has already ordered 100 million doses of the potential vaccine, while the Uk has entered into an agreement on 30 million doses.
The british-Swedish company working with a means to increase the immunforsvarets antibodies and T-cells, which attack coronavirusset. The vaccine is expected to be finished by the end of the year, and several countries, including Germany and the united kingdom have concluded agreements on the millions of doses.
Researchers from the australian institute are testing a vaccine that was developed in the beginning of the 19th century as protection against tuberculosis. The vaccine has previously set out to train the immune system to recognize and respond to infections.
Sources: New York Times, news agency Ritzau.